Bharti Mangla, Suresh Kumar Joshi, Kushagra Khanna, Prakhar Kapoor, Ipsita Kukreja


Hyaluronic is a high molecular weight naturally occurring bio-polysaccharide. It is a major component of the extracellular matrix and found in connective tissues, vitreous fluid of eye, umbilical cords and chicken combs. HA has been used in biomedical applications and in the field of drug delivery system. This review describes the applications of hyaluronic acid in various fields. It is used as such or encapsulated into different types of nano carriers, as a ligand to prepare nano-platforms for actively targeting drugs, proteins, peptides, genes, and diagnostic agents. The current therapeutic application of HA in the field of osteoarthritis, dermatology and wound healing, surgery, tissue engineering, chondro-protective effects, anaesthetic medicine, anti-adhesion and cardiovascular have also been described.


Hyaluronic acid, Chondro protective, Bio-polysaccharide

Full Text:

Full text in pdf


Arpicco S, Lerda C, DallaPozza, E, et al. Hyaluronic acid-coated liposomes for active targeting of gemcitabine. Eur J Pharm Biopharm. 2013;85:373–380.

Banzato A, Bobisse S, Rondina M, et al. A paclitaxel-hyaluronanbioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin Cancer Res. 2008;14:3598–3606.

Brown M B, Jones SA.Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin. Journal of European Academy of Dermatology and Venereology. 2005;19:308–318.

Cai S, Thati S, Bagby TR, et al. Localized doxorubicin chemotherapy with a biopolymericnanocarrier improves survival and reduces toxicity in xenografts of human breast cancer. J Control Release. 2010;146:212–218.

Cerroni B, Chiessi E, Margheritelli S, et al. Polymer shelled microparticles for a targeted doxorubicin delivery in cancer therapy. Biomacromolecules. 2011;12:593–601

Cho HJ, Yoon HY, Koo H, et al. Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and pluronic for tumor-targeted delivery of docetaxel. Biomaterials. 2011;32:7181–7190.

Cohen SM, Mukerji R, Cai S, et al. Subcutaneous delivery of nanoconjugated doxorubicin and cisplatin for locally advanced breast cancer demonstrates improved efficacy and decreased toxicity at lower doses than standard systemic combination therapy in vivo. Am J Surg. 2011;202:646–653.

Dong Z, Zheng W, Xu Z, et al. Improved stability and tumor targeting of 5‐fluorouracil by conjugation with hyaluronan. J ApplPolym Sci. 2013;130:927–932.

Drobnik J. Hyaluronan in drug delivery. Adv Drug Deliv Rev. 1991;7:295–308.

Dufay Wojcicki A, Hillaireau H, Nascimento TL, et al. Hyaluronic acid-bearing lipoplexes: Physico-chemical characterization and in vitro targeting of the CD44 receptor. J Control Release. 2012;162:545–552.

Eliaz RE, Szoka FC. Liposome-encapsulated doxorubicin targeted to CD44: A strategy to kill cd44-overexpressing tumor cells. Cancer Res. 2001;61:2592–2601.

Fraser JRE, Laurent TC, Laurent UBG. Hyaluronan: Its nature, distribution, functions and turnover.Journal of Internal Medicine. 1997;242:27–33.

Garcia-Abuin D, Gomez-Diaz JM, Navaza L, et al. Viscosimetric behaviour of hyaluronic acid in different aqueous solutions.Carbohydrate Polymers. 2011;85:500–505.

Geim AK. Graphene: Status and prospects. Science. 2009;324:1530–1534.

Goh EJ, Kim KS, Kim YR, et al. Bioimaging of hyaluronic acid derivatives using nanosized carbon dots. Biomacromolecules. 2012;13:2554–2561.

Gong H, Peng R, Liu Z. Carbon nanotubes for biomedical imaging: The recent advances. Adv Drug Delivery Rev. 2013;65:1951–1963.

Hardwicke J, Ferguson EL, Moseley R, et al. Dextrin–rhEGF conjugates as bioresponsivenanomedicines for wound repair. J Control Release. 2008;130:275–283.

Hascall VC, Calabro A, Oken MM, et al. Characterization of hyaluronan synthase expression and hyaluronan synthesis in bone marrow mesenchymalprogenitor cells: Predominant expression of HAS1 mRNA and up-regulated hyaluronansynthesis in bone marrow cells derived from multiple myeloma patients.Blood. 2002;100:2578–2585.

He M, Zhao Z, Yin L, et al. Hyaluronic acid coated poly(butyl cyanoacrylate) nanoparticles as anticancer drug carriers. Int J Pharm. 2009;373:165–173.

Hokputsa S, Jumela K, Alexander C, et al. Hydrodynamic characterisation of chemically degraded hyaluronic acid. Carbohydrate Polymers. 2003;52:111–117.

Jain A, Jain SK. In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors. Eur J Pharm Sci. 2008;35:404–416.

Jain A, Jain SK, Ganesh N, et al. Design and development of ligandappendedpolysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer. Nanom. Nanotechnol. Biol Med. 2010;6:179–190.

Karjalainen J.M., Tammi R.H., Tammi M.I., Eskelinen M.J., Agren U.M., Parkkinen J.J., Alhava E.M., Kosma V.M. (2000): Reduced level of CD44 and hyaluronan associated with unfavorable prognosis in clinical stage I cutaneous melanoma. Am J Pathol, 157, 957–965.

Kim J, Park K, Hahn SK. Effect of hyaluronic acid molecular weight on the morphology of quantum dot-hyaluronic acid conjugates. Int J BiolMacromol. 2008;42:41–45.

Kim KS, Park SJ, Goh EJ, et al. Bioimaging for targeted delivery of hyaluronic acid derivatives to the livers in cirrhotic mice using quantum dots. ACS Nano. 2010;4:3005–3014.

Kwag DS, Park K, Oh KT, et al. Hyaluronated fullerenes with photoluminescent and antitumoral activity. Chem Comm. 2013;49:282–284.

Linhardt R J. Analysis of glycosaminoglycans with polysaccharidelyases.CurrentProtocol Molecular Biology. 2001;17:13B.

Lee H, Ahn CH, Park TG. Poly[lactic-co-(glycolic acid)]-grafted hyaluronic acid copolymer micelle nanoparticles for target-specific delivery of doxorubicin. MacromolBiosci. 2009;9:336–342.

Li SD, Howell SB. CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases. Mol Pharm. 2010;7:280–290.

Liu Y, Sun J, Cao W, et al. Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery. Int J Pharm. 2011;421:160–169.

McKee C.M., Penno M.B., Cowman M., Burdick M.D., Strieter R.M., Bao C., Noble P.W. (1996): Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J. Clin. Invest 98, 2403–2413.

Medina J M, Thomas A, Denegar C R. Knee osteoarthritis: Should your patient opt for hyaluronic acid injection?. Journal of Family Practice. 2006; 8: 667–675.

Mero A, Pasqualin M, Campisi M, et al. Conjugation of hyaluronan to proteins. CarbohydrPolym. 2013;92:2163–2170.

Meyer K, Palmer J W. The polysaccharide of the vitreous humor. Journal of Biology and Chemistry. 1934; 107: 629–634.

Montagner I M, Banzato A, Zuccolotto G, et al. Paclitaxel–hyaluronanhydrosolublebioconjugate: Mechanism of action in human bladder cancer cell lines. UrolOncolSeminOrigInvestig. 2003;31:1261–1269.

Noble P.W. Hyaluronan and its catabolic products in tissue injury and repair. Matrix Biology. 2002;21:25–29.

Oertli B., Fan X., Wuthrich R.P. (1998): Characterization of CD44-mediated hyaluronan binding by renal tubular epithelial cells. NEPHROL DIAL TRANSP, 13, 271–278

Oh EJ, Choi J, Kim H, et al. Anti-Flt1 peptide–hyaluronate conjugate for the treatment of retinal neovascularization and diabetic retinopathy. Biomaterials. 2011;32:3115–3123.

Pitarresi G, Palumbo FS, Albanese A, et al. Self-assembled amphiphilic hyaluronic acid graft copolymers for targeted release of antitumoral drug. J Drug Targeting. 2010;18:264–276.

Pure E, Assoian RK. Rheostatic signaling by CD44 and hyaluronan. Cellular Signaling. 2009; 21: 651–655.

Ruhela D, Riviere K, Szoka FC. Efficient synthesis of an aldehyde functionalized hyaluronic acid and its application in the preparation of hyaluronan-lipid conjugates. Bioconjugate Chem. 2006;17:1360–1363.

Sasisekharan R, Raman R, Prabhakar V. Glycomics approach to structure function relationships of glycosaminoglycans. Annu Rev Biomed Eng. 2006; 8: 181–231.

Schanté CE, Zuber G, Herlin C, et al. Chemical modifications of hyaluronic acid for the synthesis of derivatives for a broad range of biomedical applications. CarbohydrPolym. 2011;85:469–489.

Serafino A, Zonfrillo M, Andreola F, et al. Cd44-targeting for antitumor drug delivery: A new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis. Curr Cancer Drug Targets. 2011;11:572–585.

Surace C, Arpicco S, Dufay-Wojcicki A, et al. Lipoplexes targeting the CD44 hyaluronic acid receptor for efficient transfection of breast cancer cells. Mol Pharm. 2009;6:1062–1073.

Toole BP. Hyaluronan in morphogenesis. J Gen Intern Med. 1997; 242: 35–40.

Toole BP, Wight TN, Tammi MI. Hyaluronancell interactions in cancer and vascular disease. Journal of Biological Chemistry. 2002;277:4593–4596.

Tringali G, Bettella F, Greco MC, et al. Pharmacokinetic profile of oncofid-s after intraperitoneal and intravenous administration in the rat. J. Pharm. Pharmacol. 2012;64:360–365.

Tzircotis G., Thorne R.F., Isacke C.M. (2005): Chemotaxis towards hyaluronan is dependent on CD44 expression and modulated by cell type variation in CD44-hyaluronan binding. J CELL SCI118, 5119–5128.

Upadhyay KK, Mishra AK, Chuttani K, et al. The in vivo behavior and antitumor activity of doxorubicin-loaded poly(Lbenzyl L-glutamate)-block-hyaluronanpolymersomes in ehrlich ascites tumor-bearing Balb/c mice. Nanomed. Nanotechnol. Biol Med. 2012;8:71–80.

Volpi N, Schiller J, Stern R, Soltes L., Role, metabolism, chemical modifications and applications of hyaluronan, Current medicinal chemistry, 2009;16(14):1718-45.

Xin D, Wang Y, Xiang J. The use of amino acid linkers in the conjugation of paclitaxel with hyaluronic acid as drug delivery system: Synthesis, self-assembled property, drug release, and in vitro efficiency. Pharm Res. 2010;27:380–389.

Yadav AK, Mishra P, Mishra AK, et al. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin. Nanomed. Nanotechnol. Biol Med. 2007;3:246–257

Yadav AK, Agarwal A, Rai G, et al. Development and characterization of hyaluronic acid decorated PLGA nanoparticles for delivery of 5-fluorouracil. Drug Delivery. 2010;17:561–572.


  • There are currently no refbacks.

Copyright © 2015 BIOPHARM JOURNAL  - ISSN 2454-1397 & Powered by Sona Nfinity